PCSK9 - new perspectives for lipid-lowering pharmacotherapy in patients with coronary artery disease
Optimal hypolipemic therapy reduces the risk of cardiovascular death. The drugs used in Poland are: statins, ion exchange resins, cholesterol absorption inhibitors, fibrates and proprotein subtylsin/cexin type 9 converting enzyme inhibitors (PCSK9). The function of PCSK9 is to bind receptors for LDL...
Uloženo v:
| Hlavní autoři: | , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Polonês |
| Vydáno: |
Polish Pharmaceutical Society
2020-07-01
|
| Edice: | Farmacja Polska |
| Témata: | |
| On-line přístup: | https://www.ptfarm.pl/download/?file=File%2FFarmacja+Polska%2F2020%2F6%2F02_OG_PCSK9_n.pdf |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
